| Ytd | -39.58% | |
| 1y | -46.19% |
| Open | 233.88 | Prev Close | 237.10 | Low | 233.33 | High | 243.02 | Mkt Cap | 32.18B |
| Vol | 632.87K | Avg Vol | 1.74M | EPS | 5.74 | P/E | 41.89 | Forward P/E | 18.84 |
| Beta | 0.30 | Short Ratio | 2.29 | Inst. Own | 101.70% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 10-29 | 50-d Avg | 261.93 | 200-d Avg | 326.05 | 1yr Est | 370.20 |
ALNY News
Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY), the leading RNAi therapeutics company, today announced
Shares of Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY - Get Free Report) have been given a consensus
[url="]Alnylam Pharmaceuticals, Inc[/url]. (Nasdaq: ALNY), the leading RNAi therapeutics company, to
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi th
Alnylam Pharmaceuticals (NASDAQ:ALNY) has outperformed the market over the past 20 years by 5.86% on
NEW YORK, Aug. 26, 2026 (GLOBE NEWSWIRE) -- The law firm of Kirby McInerney LLP continues its invest
Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY), the leading RNAi therapeutics company, today announced
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi th
(NASDAQ: ALNY) Investor Alert: Kessler Topaz Meltzer and Check, LLP Encourages Alnylam Pharmaceutica
RADNOR, Pa., Aug. 22, 2026 /PRNewswire/ -- Kessler Topaz Meltzer & Check, LLP (www.ktmc.com), a nati
RADNOR, Pa., Aug. 21, 2026 (GLOBE NEWSWIRE) -- Kessler Topaz Meltzer & Check, LLP (www.ktmc.com), a
If you purchased or acquired stock in Alnylam and would like to discuss your legal rights, contact B
Biotech stocks are having one of their best stretches in years. The iShares Biotechnology ETF (NASDA
The iShares Biotechnology ETF is trading at new highs and 18 out of its top 20 constituents are gree
LOS ANGELES, Aug. 20, 2026 (GLOBE NEWSWIRE) -- Glancy Prongay Wolke & Rotter LLP, a leading national
BENSALEM, Pa., Aug. 20, 2026 (GLOBE NEWSWIRE) -- Law Offices of Howard G.
The law firm of [url="]Kirby McInerney LLP[/url] reminds investors of its investigation on behalf of
NEW YORK--(BUSINESS WIRE)---- $ALNY #ClassActionLawsuit--The law firm of Kirby McInerney LLP reminds
LOS ANGELES, Aug. 19, 2026 (GLOBE NEWSWIRE) -- The Law Offices of Frank R. Cruz continues its invest
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analys
Top analysts change outlook on ALNY, AGMB, BMRN, BEKE, and IONS with ratings and price targets. Chec
BMO Capital analyst David Lebowitz initiates coverage on Alnylam Pharmaceuticals (NASDAQ:ALNY) wi
Investor Alert: Kessler Topaz Meltzer and Check, LLP Encourages Alnylam Pharmaceuticals, Inc. (NASDA
RADNOR, Pa., Aug. 16, 2026 /PRNewswire/ -- Kessler Topaz Meltzer & Check, LLP (www.ktmc.com), a nati
Alnylam's stock has plunged due to a revenue guidance cut and other concerns. However, the full stor
RADNOR, Pa., Aug. 15, 2026 (GLOBE NEWSWIRE) -- Kessler Topaz Meltzer & Check, LLP (www.ktmc.com), a
Wells Fargo analyst Derek Archila maintains Alnylam Pharmaceuticals (NASDAQ:ALNY) with a Equal-We
Alnylam Pharmaceuticals (NASDAQ:ALNY) has outperformed the market over the past 20 years by 5.9% on
Truist Securities analyst Danielle Brill maintains Alnylam Pharmaceuticals (NASDAQ:ALNY) with a B
HC Wainwright & Co. analyst Patrick R. Trucchio maintains Alnylam Pharmaceuticals (NASDAQ:ALN
Raymond James analyst Martin Auster upgrades Alnylam Pharmaceuticals (NASDAQ:ALNY) from Outperfor
Citigroup analyst Eric Joseph maintains Alnylam Pharmaceuticals (NASDAQ:ALNY) with a Buy and lowe
Barclays analyst Eliana Merle maintains Alnylam Pharmaceuticals (NASDAQ:ALNY) with a Overweight a
JP Morgan analyst Jessica Fye maintains Alnylam Pharmaceuticals (NASDAQ:ALNY) with a Overweight a
RBC Capital analyst Luca Issi maintains Alnylam Pharmaceuticals (NASDAQ:ALNY) with a Outperform a
Morgan Stanley analyst Michael Ulz maintains Alnylam Pharmaceuticals (NASDAQ:ALNY) with a Equal-W
Oppenheimer analyst Kostas Biliouris maintains Alnylam Pharmaceuticals (NASDAQ:ALNY) with a Outpe
Wells Fargo analyst Derek Archila maintains Alnylam Pharmaceuticals (NASDAQ:ALNY) with a Equal-We
Stifel analyst Paul Matteis maintains Alnylam Pharmaceuticals (NASDAQ:ALNY) with a Buy and lowers
Needham analyst Joseph Stringer maintains Alnylam Pharmaceuticals (NASDAQ:ALNY) with a Buy and lo
Alnylam cut its 2026 sales outlook despite a Q2 earnings beat as slower ATTR-CM market growth weighe
Microsoft's 43% cloud growth revived the AI trade and lifted chipmakers, but Meta's guidance
Gainers Nuwellis (NASDAQ:NUWE) stock moved upwards by 123.7% to $4.23 during Thursday's regular
US stocks gain, Dow up 300 points as tech shares surge 5.3%, Bristol-Myers Squibb beats expectation
Alnylam Pharmaceuticals (NASDAQ:ALNY) lowers FY2026 sales outlook from $5.300 billion-$5.800 billion
Alnylam Pharmaceuticals (NASDAQ:ALNY) reported quarterly earnings of $1.84 per share which beat the
JP Morgan analyst Jessica Fye maintains Alnylam Pharmaceuticals (NASDAQ:ALNY) with a Overweight a
− Initiates Global Phase 2 APPlauDS Study of Mivelsiran in Down Syndrome–Associated Alzheimer’s Dise
B of A Securities analyst Tazeen Ahmad maintains Alnylam Pharmaceuticals (NASDAQ:ALNY) with a Buy
Truist Securities analyst Danielle Brill maintains Alnylam Pharmaceuticals (NASDAQ:ALNY) with a B